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Abstract: Prevalence of hypertension in children and adolescents has progressively and 
continuously increased over recent decades. Thus, early and effective control of high blood 
pressure may be considered an effective therapeutic approach, in order to reduce the burden of 
hypertension-related cardiovascular disease in future. In the past, due to the absence of prospec-
tive, long-term, randomized, controlled clinical trials performed in young hypertensive patients, 
lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. 
More recently, clinical data on the efficacy and safety of five major classes of antihypertensive 
drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers 
[ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In   particular, 
these trials demonstrated dose-dependent blood pressure reductions and a good tolerability 
profile of several ARBs in hypertensive children and adolescents. An overview is provided of 
the clinical benefits of early detection and prompt intervention of high blood pressure levels, 
with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young 
subjects with hypertension.
Keywords: hypertension, high blood pressure, children, adolescents, antihypertensive   treatment, 
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Introduction
Effective treatment of high blood pressure (BP) represents a key strategy in reducing 
the burden of cardiovascular (CV) and renal diseases.1–3 Consistent findings have 
demonstrated significant reductions in CV and renal morbidity and mortality through 
the systematic use of different BP-lowering strategies in adult populations.4–7 In spite 
of these well-established concepts, hypertension remains poorly controlled in both 
Western countries8,9 and in developing countries.10–12 In view of the progressively 
increasing prevalence of hypertension in children and adolescents,13,14 early and effec-
tive control of BP may be considered an effective therapeutic approach for reducing 
the burden of hypertension-related CV disease.
Observational surveys have demonstrated that high BP levels are frequently 
associated with other concomitant CV risk factors, including obesity, dyslipidemia, 
metabolic syndrome, and diabetes in young individuals.15–18 This clustering of   multiple, 
concomitant CV risk factors may exert different effects according to target   populations: 
while in adulthood it raises the susceptibility for developing major CV and renal 
events, including acute myocardial infarction, stroke, and heart and renal failure,19,20 in 
childhood it may substantially promote an acceleration of the risk of developing estab-
lished CV disease in adult age.21,22 In other words, young subjects with high BP   levels, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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hypercholesterolemia, metabolic syndrome, or impaired 
glucose regulation have greater susceptibility to develop 
these clinical conditions with aging, thus contributing to an 
increased burden of CV disease in the general population. 
These features make hypertension a potential target to reduce 
CV morbidity in young subjects and to improve prevention 
of CV morbidity and mortality in adult individuals.23
This latter point has prompted the search for agents or 
strategies that exert an early and effective BP control and 
that, at the same time, are able to provide benefits in terms 
of organ protection, beyond BP-lowering effects, with a low 
incidence of side effects and good tolerability profile, which 
represents important properties in young individuals.24,25
In view of the progressively large diffusion of hyper-
tension and BP-related clinical diseases in children and 
adolescents, and of the objective difficulties of applying 
lifestyle changes in this specific age group, the use of antihy-
pertensive drugs, especially in those patients not controlled 
with   lifestyle changes, may enable improved BP control and 
reduce the burden of CV disease in young individuals.
This paper provides an overview of the main findings of a 
recent clinical trial, performed with olmesartan medoxomil in 
young individuals, and discusses the clinical benefits derived 
from early detection and prompt intervention of high BP 
levels in children and adolescents. According to the aim of 
our study, a comprehensive search strategy was performed 
through online medical databases (Medline and Embase) 
by using the following search terms: “hypertension”, “high 
blood pressure”, “children”, “adolescents”, “olmesartan 
medoxomil”. Among the large number of articles made 
available from this research, only those which have been 
published in English, in peer-reviewed journals, and with 
full access to entire contents of the paper have been selected 
and discussed in this paper.
Hypertension management  
in children and adolescents
Diagnostic criteria for high BP levels in children and adoles-
cents are based on the concept that BP progressively increases 
according to age, height and body size.26,27 Since a single BP 
threshold to define hypertension is not applicable in young 
individuals, BP targets are commonly defined in relation to 
the distribution of BP in the normal young population. Thus, 
normal BP in children and adolescents is defined as systolic 
and diastolic BP levels less than the 90th percentile for age, 
sex, and height, whereas hypertension is defined as systolic 
and diastolic BP levels persistently on the 95th percentile or 
more, measured on at least three separate visits.26,27
As for hypertension definition, BP targets to be achieved 
with treatment vary according to the characteristics of general 
population.26,27 In the past, lifestyle changes have been highly 
recommended to reduce high BP levels in young hypertensive 
patients. More recently, international guidelines recommend 
that, when required and usually after a 3- to 6-month period 
of lifestyle changes, antihypertensive treatment should be 
started with a single drug administered at a low dose, in order 
to avoid a rapid fall in BP.26–28
When antihypertensive drug therapy is needed, the first 
choice of antihypertensive agents can be made among all five 
classes of antihypertensive drugs.26,27 This is mostly based on 
the fact that only few placebo-controlled studies are   available, 
but almost no head-to-head studies directly comparing the 
efficacy and safety of different antihypertensive drugs in 
children or adolescents have been conducted. Since the 
rennin–angiotensin system (RAS) is intimately involved in 
different pathophysiological mechanisms leading to develop-
ment and progression of hypertension, RAS blocking agents, 
such as angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs), are now viewed 
as suitable and useful therapeutic tools to antagonize the 
deleterious consequences of RAS abnormal activity in 
hypertension-related disease conditions, including metabolic 
syndrome,29 diabetes,30 and organ damage,31 in the presence 
of an effective BP-lowering efficacy and good tolerability 
profile. In this regard, a recent analysis of 27 clinical trials 
performed in young individuals with hypertension reported 
comparable BP reductions with ACE inhibitors, ARBs, and 
calcium-channel blockers.32 In particular, clinical data on 
the efficacy, safety, and tolerability of ARB-based therapy 
in hypertensive children have become recently available. 
These trials demonstrated dose-dependent BP reductions 
and a good tolerability profile of several ARB compounds, 
such as losartan 0.75 to 1.44 mg/kg, candesartan 0.16 to 
0.47 mg/kg, valsartan 2 mg/kg per day, and irbesartan 75 
to 150 mg daily.26 More recently, interesting clinical data 
demonstrating the efficacy and tolerability of olmesartan 
medoxomil have become available.33
Pharmacodynamics, 
pharmacokinetics and clinical 
efficacy of olmesartan
Pharmacodynamics
Olmesartan medoxomil is an orally administered prodrug 
of olmesartan, a non-peptide ARB that has high selectivity 
for the AT1 receptor, to which it is highly bound, having 
a limited affinity to the AT2 receptor.34 Since activation Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of the AT1 receptor by angiotensin II induces arteriolar 
  vasoconstriction, sympathetic nervous system activation, salt 
and water retention, and aldosterone secretion,35 olmesartan 
is presumed to reduce high BP levels mostly by blocking 
the vasoconstrictor and aldosterone-secreting effects of 
angiotensin II.36,37 Consistent with this mechanism of action, 
animal and human studies demonstrated that the effects of 
olmesartan medoxomil on BP parallel the inhibitory effects 
on RAS activation.36
In animal models, olmesartan also reduced produc-
tion of markers of early CV inflammation,38 myocardial 
remodeling,39 and cardiac fibrosis.40 In addition, it reduced 
in a dose-dependent fashion urinary protein excretion and 
the area of plaque lesions and intimal wall thickening in 
cross sections of the aorta.41 In patients with hypertension, 
olmesartan produces gradual and sustained dose-dependent 
reductions in both systolic and diastolic BP levels, with-
out first-dose hypotension, tachyphylaxis during extended 
treatment or rapid rebound hypertension, when treatment is 
discontinued.42,43
Pharmacokinetics
Olmesartan medoxomil is a prodrug that is rapidly   hydrolyzed 
into olmesartan in the gastrointestinal tract.36,44 It is rapidly 
absorbed from the gastrointestinal tract, with a maximum 
plasma concentration (Cmax) of 0.22 to 2.1 mg/L, a time to Cmax 
of 1.4 ti 2.8 hours, and a mean area under the concentration-
time curve (AUC) of 1.6 ti 19.9 mgh/L, following administra-
tion of olmesartan medoxomil 10 to 160 mg.45
Olmesartan is the only metabolite of olmesartan 
  medoxomil. It is excreted mainly in the feces (about 60%) and 
the urine; in children, approximately 3% to 15% was recovered 
in the urine.46 The mean terminal elimination half-life was 12 
to 18 hours for 20 mg olmesartan,45 which compares favor-
ably with the half-lives of some other ARBs: irbesartan (11 
to 15 hours), losartan (2 hours) and its active metabolite (4 to 
5 hours), and valsartan (6 hours).47 Finally, olmesartan is not 
metabolized by cytochrome P-450 enzymes and, therefore, it 
is unlikely to interact with other drugs that inhibit, induce, or 
are metabolized by cytochrome P-450 enzymes.48,49
The pharmacokinetics of oral olmesartan medoxomil 
have been investigated in relatively small, open-label studies 
performed in pediatric patients with hypertension.50 More 
recently, the antihypertensive efficacy, safety, and tolerability 
of oral olmesartan medoxomil in the treatment of hyperten-
sion in children and adolescents (aged 6 to 16 years) was 
investigated in a randomized, double-blind, multinational, 
phase II/III trial.33 The main findings of this study confirmed 
the potential benefits derived from the use of this drug in the 
young population, in terms of BP-lowering efficacy and a 
good tolerability profile.50
Clinical efficacy, safety, and tolerability  
in children and adolescents
The Assessment of Efficacy and Safety of Olmesartan in 
Pediatric Hypertension (AESOP) study33 was a random-
ized, multicenter, double-blind, parallel-group, dose-ranging 
prospective clinical trial performed in young individuals of 
any race, aged 6 to 16 years, and presenting with primary 
or   secondary hypertension. The primary endpoint was 
the   efficacy and safety profile of olmesartan medoxomil 
in   children and adolescents with hypertension, defined as 
systolic BP above the 95th percentile for age, gender, and 
height.33 This trial was specifically requested by the United 
States Food and Drug Administration, for approving drug 
prescriptions in young individuals.
The trial was conducted in two distinct periods, with two 
cohorts in each period. Enrolled individuals were stratified 
according to ethnicity (cohort A: 62% Caucasian, 18% Black, 
10% Asian, and 14% other races; cohort B, 100% Black). 
In period 1, patients were randomized to receive either low-
dose (2.5 to 5 mg) or high-dose (20 to 40 mg) olmesartan daily 
for 3 weeks. In period 2, patients maintained their olmesartan 
dose (active treatment) or initiated placebo washout for an 
additional 2 weeks.
Among 422 individuals who were initially screened, 302 
were randomly assigned to the two cohorts (cohort A: n = 190 
and cohort B: n = 112). In particular, 95 and 56 patients were 
randomly assigned to each of the olmesartan dose groups in 
cohort A and B, respectively.
During the first period, the primary efficacy analyses were 
based on the changes from baseline in trough seated systolic 
and diastolic BP levels at the end of period 1 in cohorts. 
Reductions in both systolic and diastolic BP levels were 
consistently greater in the high-dose group than in the 
low-dose group, and they were smaller in cohort B than in 
cohort A. These differences were statistically significant, 
even after adjustment for baseline body weight.
Among patients included in period 1 analysis, 13 
individuals did not enter period 2, resulting in a total of 182 
patients in cohort A and 107 patients in cohort B, respectively. 
BP changes were analyzed from period 2 baseline (end of 
period 1) through the end of period 2 (last observation carried 
forward). Among patients included in cohort A, the mean 
increase in seated systolic BP was 0.43 mmHg for subjects 
on active treatment and 4.9 mmHg for subjects receiving Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
180
Tocci and Volpe
placebo (BP difference between active treatment and placebo 
of −3.6 mmHg; P = 0.0093). Among individuals included in 
cohort B, the mean seated systolic BP increase (1.4 mmHg) 
for subjects on active treatment was lower than that reported 
in subjects on placebo (3.8 mmHg; P = NS).
The percentage of patients experiencing a treatment-
emergent adverse event within each cohort was low and 
similar for the low- and high-dose active treatment groups. 
The majority of adverse effects were mild or moder-
ate in intensity and were considered unrelated to active 
therapy.
Conclusions and perspectives
Hypertension in children and adolescents is a growing 
  epidemiological problem. The progressive rise of average 
BP levels among young individuals definitely parallels the 
  dramatic increase in overweight, obesity, metabolic syn-
drome, impaired glucose regulation, and diabetes that we 
are witnessing. Therefore, a higher commitment to the mea-
surement of BP, diagnosis of hypertension, and therapeutic 
interventions (virtuous lifestyle changes and drug therapy, 
when required) should be undertaken and promoted in young 
subjects.
Population strategies to prevent development of hyperten-
sion at a young age, with particular regard to the quality of 
diet, routine exercise or regular physical activity, and banning 
of cigarette smoking, need to be actively promoted. Similar 
measures should be also applied at a clinical level in the 
individual patient, especially when concomitant predisposing 
risk factors are present.
Drug therapy should be undertaken prudently, when 
required. Drugs that may provide a satisfactory BP control 
in monotherapy and that have few side effects and do not 
interfere with the quality of life in children and adolescents 
are highly recommended.26,27 In this regard, ARBs have 
been sufficiently explored in young hypertensive patients, 
and seem to have a substantially good record. Among these 
drugs, olmesartan medoxomil has been recently tested with 
a rigorous clinical trial program in a population of children 
and adolescents aging from 6 to 16 years and belonging 
to Caucasian or Black ethnic groups.33 The results of this 
study have been satisfactory in terms of BP reduction and 
tolerability profile.33 Together with the organ protection and 
the neutral metabolic effects provided by ARBs through the 
selective antagonism of RAS, olmesartan appears to hold 
more than a good promise for an effective and safe treatment 
of children and adolescents with hypertension.
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